The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenue | 4,632 |
| Total operating expenses | 212,982 |
| Total other income, net | 7,208 |
| Net loss | -201,142 |
| Stock-based compensation expense | 29,268 |
| Non cash lease expense | 9,698 |
| Depreciation expense | 7,321 |
| Change in fair value of short-term investment related party | 432 |
| Amortization of premiums and discount on short-term investments | 1,937 |
| Prepaid expenses and other current assets | -4,545 |
| Accounts payable | 996 |
| Accrued expenses and other current liabilities | -1,160 |
| Accrued settlement payment related party | 0 |
| Deferred revenue related party | -4,359 |
| Lease liability | -5,362 |
| Net cash used in operating activities | -162,564 |
| Maturities of investments | 95,781 |
| Sales of investments related party | 5,400 |
| Purchases of investments | 205,413 |
| Purchases of property and equipment | 4,531 |
| Return (payment) of security deposit | 0 |
| Net cash (used in) provided by investing activities | -108,763 |
| Proceeds from follow-on offering, net of issuance costs | 138,390 |
| Proceeds from research and development funding liability | 12,000 |
| Net proceeds from stock option exercises | 781 |
| Proceeds from espp offerings | 341 |
| Proceeds from issuance of common stock under the bms securities purchase agreement related party | 0 |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | 0 |
| Net cash provided by financing activities | 151,512 |
| Net change in cash, cash equivalents, and restricted cash | -119,815 |
| Cash, cash equivalents, and restricted cash at beginning of period | 196,538 |
| Cash, cash equivalents, and restricted cash at end of period | 76,723 |
Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. (PRME)